Under construction – not a live service
Sign in
Taking people in ChinaNo phase

IgA Nephropathy Registration Initiative of High Quality (INSIGHT)

Key facts

Where
Guangzhou, ChinaSee the site

Where in China

  • The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Sun Yat-sen University
Trial code
NCT03001947
Record updated
15 September 2026
Original description
The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients at recruited hospitals and developing a IgAN database in China. Patients will be follow-up every one year, and both baseline and follow-up information will be entered into the registration system. All-cause and cardiovascular mortality and a composite renal outcome of doubling of serum creatinine and end stage renal failure (ESRD, defined as initiation of dialysis or kidney transplantation) of IgAN patients will be compared using the IgAN database.Read full original descriptionShow less

The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients at recruited hospitals and developing a IgAN database in China. Patients will be follow-up every one year, and both baseline and follow-up information will be entered into the registration system. All-cause and cardiovascular mortality and a composite renal outcome of doubling of serum creatinine and end stage renal failure (ESRD, defined as initiation of dialysis or kidney transplantation) of IgAN patients will be compared using the IgAN database.

Inclusion: Biopsy-proven primary IgAN patients; age ≥14 years old; Adequate biopsy sample containing ≥8 glomeruli.

Exclusion: Secondary causes of mesangial IgA deposition, such as Henoch-Schonlein purpura nephritis, systemic lupus erythematosus, liver cirrhosis and et al; eGFR≤15ml/min/1.73m2 at biopsy.

ClinicalTrials.gov NCT03001947